Frankfurt
11.11.26 | 09:55
3,320 Euro
-0,60 % -0,020
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Inventiva auf Guggenheim Healthcare Conference: Lanifibranor vor entscheidendem Phase-III-Readout | 5 | Investing.com Deutsch | ||
| 28.10. | Inventiva (IVA) vs. CRSP and MDGL: Can Lanifibranor's Phase 3 Trial Unlock 62% Upside? | 33 | Insider Monkey | ||
| 06.10. | Inventiva S.A. - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 06.10. | INVENTIVA: Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting 2026 | 712 | GlobeNewswire (Europe) | Preclinical data showed that balanced PPARa, PPARd and PPAR? activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesisPreclinical... ► Artikel lesen | |
| 04.10. | Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth? | 12 | Insider Monkey | ||
| 30.09. | Inventiva Ends First Half With €233.9 Million In Cash And Deposits Ahead Of Phase 3 NATiV3 Results | 11 | pulse2.com | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 30.09. | Inventiva auf Stifel-Forum für Kardiometabolik: Lanifibranor vor entscheidendem Test | 15 | Investing.com Deutsch | ||
| 28.09. | Truist bestätigt Kaufempfehlung für Inventiva Aktie vor Phase-3-Daten | 24 | Investing.com Deutsch | ||
| 28.09. | Truist reiterates Buy on Inventiva stock ahead of phase 3 data | 5 | Investing.com | ||
| 28.09. | Inventiva H1 2026 Earnings Call: Complete Transcript | 2 | Benzinga.com | ||
| 28.09. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.09. | Inventiva S.A reports 1H results | 7 | Seeking Alpha | ||
| 28.09. | Inventiva H1 Loss Drops | 12 | RTTNews | ||
| 28.09. | INVENTIVA: Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update | 893 | GlobeNewswire (Europe) | Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits1 as of June 30, 2026Cash runway guidance remains unchanged from July 30, 20262Topline results of the Phase 3 NATiV3... ► Artikel lesen | |
| 23.09. | Stifel reiterates Buy on Inventiva stock, $15 target on MASH drug | 17 | Investing.com | ||
| 18.09. | Stifel reiterates Buy on Inventiva stock ahead of trial data | 11 | Investing.com | ||
| 15.09. | Guggenheim raises Inventiva stock price target on trial outlook | 11 | Investing.com | ||
| 08.09. | INVENTIVA: Inventiva to Present Multiple Abstracts at Paris MASH 2026 | 907 | GlobeNewswire (Europe) | Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetesPreclinical data further characterize... ► Artikel lesen | |
| 03.09. | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.09. | INVENTIVA: Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH | 1.404 | GlobeNewswire (Europe) | Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September... ► Artikel lesen |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 0,380 | +4,97 % | EyePoint auf der Stifel Healthcare Conference 2026: Strategischer Schwenk auf DME nach Rückschlag bei feuchter AMD | ||
| EDWARDS LIFESCIENCES | 93,52 | +0,36 % | Edwards Lifesciences Corp. Q3 Income Climbs | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) released a profit for its third quarter that Increases, from last yearThe company's bottom line totaled $307.5 million, or $0.53 per share.... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,935 | +0,54 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness QSR Announces the Grand Opening of Its 55th Location in Richmond Hill, Ontario | Toronto, Ontario--(Newsfile Corp. - November 6, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 220,90 | +0,45 % | Bernstein cuts Jazz Pharmaceuticals stock price target on Zepzelca outlook | ||
| DAIICHI SANKYO | 15,996 | +0,78 % | Asking More of Science: How Daiichi Sankyo Is Challenging Assumptions About the Future of Cancer Care | ||
| AYTU BIOPHARMA | 1,900 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma to Report Fiscal 2027 First Quarter Operational and Financial Results on November 16, 2026 | DENVER, CO / ACCESS Newswire / November 10, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 38,680 | -1,88 % | Rigel outlines $290M-$295M 2026 revenue outlook as VEPPANU launch starts with $6.6M sales | ||
| NRX PHARMACEUTICALS | 2,075 | -1,66 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine | Abbreviated New Drug Application (ANDA) Amendment related to the drug vial for preservative-free ketamine has been reclassified from a Major Amendment to a Minor Amendment.FDA has revised the Generic... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 1,330 | -7,64 % | TuHURA Biosciences ruft weitere $1,5 Millionen aus bestehender Kreditfazilität ab | ||
| CGN MINING | 0,256 | -0,78 % | CGN MINING Invested Mines Produce Total of 642.4tU of Natural Uranium in 3Q | ||
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,905 | +2,84 % | SHINEWAY PHARM 9M Revenue Falls 28.3% YoY | ||
| FUTURA MEDICAL | 0,001 | 0,00 % | Futura Medical PLC - Board Change and Formal Sale Process Update | ||
| TEVA PHARMACEUTICAL INDUSTRIES | 42,390 | 0,00 % | Tourette ist mehr als sichtbare Tics: Teva und Neurothera verfolgen neue Behandlungsansätze | ||
| ETON PHARMACEUTICALS | 67,59 | 0,00 % | Eton Pharma jumps after Q3 beat and guidance hike | ||
| BAYER | 56,90 | -0,32 % | Bayer Aktie: Widerstand im Fokus | Die Aktie von Bayer hat gestern mit einem Kurssprung auf die Quartalszahlen reagiert. Das neue Jahreshoch konnten die Papiere allerdings nicht halten. Rückblick: Nach dem Rückfall an die 200-Tage-Linie... ► Artikel lesen |
INVENTIVA SA ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -0,60 % bei einem Aktienkurs von 3,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.